{"id":8949,"date":"2021-04-12T10:35:25","date_gmt":"2021-04-12T17:35:25","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=8949"},"modified":"2021-04-13T10:36:00","modified_gmt":"2021-04-13T17:36:00","slug":"real-world-effect-of-monoclonal-antibody-treatment-in-covid-19-patients-in-a-diverse-population-in-the-united-states","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/12\/real-world-effect-of-monoclonal-antibody-treatment-in-covid-19-patients-in-a-diverse-population-in-the-united-states\/","title":{"rendered":"Real-World Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> Monoclonal antibody treatment significantly reduced the risk of subsequent emergency department visit or hospitalization among patients with COVID-19 (n = 598) in a real-world study using electronic health record data. Among 270 (45%) patients treated with the monoclonal antibody bamlanivimab, 5 (1.9%) presented to the emergency department (ED) or required hospitalization within 30 days of a positive SARS-CoV-2 test, compared to 39 of <\/span><span style=\"font-weight: 400\">328 (12%) untreated patients.\u00a0The risk of <\/span><span style=\"font-weight: 400\">an <\/span><span style=\"font-weight: 400\">ED visit or hospitalization was 82% lower in <\/span><span style=\"font-weight: 400\">patients treated with <\/span><span style=\"font-weight: 400\">bamlanivimab <\/span><span style=\"font-weight: 400\">than<\/span><span style=\"font-weight: 400\"> untreated patients after adjusting for age, gender, and comorbidities.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Rainwater-Lovett et al.\u00a0(Apr 10, 2021). Real-World Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States. Pre-print downloaded Apr 12 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.04.08.21254705\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.04.08.21254705<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] Monoclonal antibody treatment significantly reduced the risk of subsequent emergency department visit or hospitalization among patients with COVID-19 (n = 598) in a real-world study using electronic health record data. Among 270 (45%) patients treated with the monoclonal antibody bamlanivimab, 5 (1.9%) presented to the emergency department (ED) or required hospitalization within&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/12\/real-world-effect-of-monoclonal-antibody-treatment-in-covid-19-patients-in-a-diverse-population-in-the-united-states\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[28],"topic":[19],"class_list":["post-8949","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-treatment","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=8949"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8949\/revisions"}],"predecessor-version":[{"id":8950,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8949\/revisions\/8950"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=8949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=8949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=8949"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=8949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}